A Test in Context: High-Sensitivity C-Reactive Protein

Area of Science:

• Cardiology
• Inflammation Biomarkers

Background:

• High-sensitivity C-reactive protein (hsCRP) is an inflammatory biomarker offering prognostic cardiovascular risk information.
• hsCRP levels (<1, 1-3, >3 mg/L) correlate with lower, average, and higher relative cardiovascular risk.
• Global cardiovascular risk algorithms incorporating hsCRP demonstrate superior performance compared to those using only Framingham covariates.

Purpose of the Study:

• To evaluate the prognostic value of hsCRP in cardiovascular risk assessment.
• To determine the efficacy of statin therapy in reducing cardiovascular events in patients with elevated hsCRP.

Main Methods:

• Analysis of hsCRP levels for cardiovascular risk stratification.
• Evaluation of data from the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

Main Results:

• The JUPITER trial demonstrated a 47% reduction in myocardial infarction, stroke, or cardiovascular death with statin use.
• This benefit was observed in patients with low-density lipoprotein cholesterol <130 mg/dL and hsCRP >2 mg/L.
• Statins showed a hazard ratio of 0.53 (95% CI: 0.40-0.69, p < 0.00001) in this patient group.

Conclusions:

• hsCRP is a valuable biomarker for assessing cardiovascular risk and guiding treatment decisions.
• Statin therapy is effective in reducing vascular events in patients identified with elevated hsCRP and low LDL-C.
• Current U.S. guidelines recommend hsCRP (Class IIb) for primary prevention when statin initiation is uncertain.